Answers are grounded in this paper and cite their sources.
Compares Japanese package inserts and overseas references on medication use in pregnancy and breastfeeding, highlighting significant differences in prohibitions.
Differences have been reported between the information provided in Japanese package inserts and that in overseas references regarding the use of medications in pregnant and breastfeeding women.However, no reports have been published since the end of the transitional period for the revised labeling rules in 2019.In this study, we examined the package inserts of 369 oral medications listed in the formulary of Tohoku Medical and Pharmaceutical University Wakabayashi Hospital as of March 2025 and compared them with overseas references (pregnancy: Drugs in Pregnancy and Lactation, 12th ed.; breastfeeding: Medications and Mothers ' Milk 2025' Milk -2026)).Package inserts prohibit the use of 90 drugs for pregnancy and 55 drugs for breastfeeding, whereas overseas sources prohibit the use of 20 and 32 drugs, respectively, indicating a larger gap for pregnancy.Among the 15 drugs prohibited for use in pregnancy according to package inserts, but considered permissible in overseas references, 14 package inserts were based on adverse events in animals.Of the five drugs prohibited for breastfeeding in the Japanese package inserts but regarded as compatible in overseas references, three inserts mentioned only drug transfer into breast milk without describing adverse events in infants.These findings suggest that further evidence is needed to support future package insert revisions.
No takes yet. Share an insight, caveat, or question.
Yashima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: